• Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=23891627; PubMed=26325104).
  

PubMed=23891627; DOI=10.1016/j.ajog.2013.07.020
English D.P., Bellone S., Cocco E., Bortolomai I., Pecorelli S., Lopez S., Silasi D.-A., Schwartz P.E., Rutherford T.J., Santin A.D.
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
Am. J. Obstet. Gynecol. 209:465.e1-465.e9(2013)

PubMed=25268372; DOI=10.1038/bjc.2014.519; PMCID=PMC4453741
Schwab C.L., Bellone S., English D.P., Roque D.M., Lopez S., Cocco E., Nicoletti R., Bortolomai I., Bonazzoli E., Ratner E., Silasi D.-A., Azodi M., Schwartz P.E., Rutherford T.J., Santin A.D.
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
Br. J. Cancer 111:1750-1756(2014)

PubMed=26325104; DOI=10.1038/bjc.2015.306; PMCID=PMC4651122
Black J.D., Lopez S., Cocco E., Bellone S., Altwerger G., Schwab C.L., English D.P., Bonazzoli E., Predolini F., Ferrari F., Ratner E., Silasi D.-A., Azodi M., Schwartz P.E., Santin A.D.
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Br. J. Cancer 113:1020-1026(2015)

PubMed=26625219; DOI=10.1038/bjc.2015.388; PMCID=PMC4705897
Black J.D., Lopez S., Cocco E., Bellone S., Altwerger G., Schwab C.L., English D.P., Bonazzoli E., Predolini F., Ferrari F., Ratner E., Silasi D.-A., Azodi M., Schwartz P.E., Santin A.D.
Erratum to: PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Br. J. Cancer 113:1641-1641(2015)